Article Type
Changed
Fri, 01/18/2019 - 11:48
Display Headline
FDA Approves First Generic Form of Escitalopram

The first generic formulation of the selective serotonin reuptake inhibitor escitalopram has been approved by the Food and Drug Administration, the agency announced on March 14.

In a statement, the FDA said that generic escitalopram – in 5-mg, 10-mg, and 20-mg doses – manufactured by Teva Pharmaceutical Industries/IVAX Pharmaceuticals, has been approved for treating depression and generalized anxiety disorder in adults. Escitalopram initially was approved in 2002 and is marketed as Lexapro by Forest Laboratories.

Teva has 180 days of generic drug "exclusivity," during which time the FDA cannot approve any other generic formulation of escitalopram, the statement said.

For more information on generic drugs, click here to access the FDA site.

Author and Disclosure Information

Publications
Topics
Legacy Keywords
generic formulation, selective serotonin reuptake inhibitor, escitalopram, the Food and Drug Administration, generic escitalopram, Teva Pharmaceutical Industries/IVAX Pharmaceuticals, depression, generalized anxiety disorder, Lexapro, Forest Laboratories
Author and Disclosure Information

Author and Disclosure Information

The first generic formulation of the selective serotonin reuptake inhibitor escitalopram has been approved by the Food and Drug Administration, the agency announced on March 14.

In a statement, the FDA said that generic escitalopram – in 5-mg, 10-mg, and 20-mg doses – manufactured by Teva Pharmaceutical Industries/IVAX Pharmaceuticals, has been approved for treating depression and generalized anxiety disorder in adults. Escitalopram initially was approved in 2002 and is marketed as Lexapro by Forest Laboratories.

Teva has 180 days of generic drug "exclusivity," during which time the FDA cannot approve any other generic formulation of escitalopram, the statement said.

For more information on generic drugs, click here to access the FDA site.

The first generic formulation of the selective serotonin reuptake inhibitor escitalopram has been approved by the Food and Drug Administration, the agency announced on March 14.

In a statement, the FDA said that generic escitalopram – in 5-mg, 10-mg, and 20-mg doses – manufactured by Teva Pharmaceutical Industries/IVAX Pharmaceuticals, has been approved for treating depression and generalized anxiety disorder in adults. Escitalopram initially was approved in 2002 and is marketed as Lexapro by Forest Laboratories.

Teva has 180 days of generic drug "exclusivity," during which time the FDA cannot approve any other generic formulation of escitalopram, the statement said.

For more information on generic drugs, click here to access the FDA site.

Publications
Publications
Topics
Article Type
Display Headline
FDA Approves First Generic Form of Escitalopram
Display Headline
FDA Approves First Generic Form of Escitalopram
Legacy Keywords
generic formulation, selective serotonin reuptake inhibitor, escitalopram, the Food and Drug Administration, generic escitalopram, Teva Pharmaceutical Industries/IVAX Pharmaceuticals, depression, generalized anxiety disorder, Lexapro, Forest Laboratories
Legacy Keywords
generic formulation, selective serotonin reuptake inhibitor, escitalopram, the Food and Drug Administration, generic escitalopram, Teva Pharmaceutical Industries/IVAX Pharmaceuticals, depression, generalized anxiety disorder, Lexapro, Forest Laboratories
Article Source

PURLs Copyright

Inside the Article